Sp934

CONVERSATION PANEL WITH DR. SELWYN VICKERS

Date
May 20, 2024

Presenter


Tracks

Related Products

Thumbnail for POSTOPERATIVE DAY 1 DRAIN AMYLASE AFTER PANCREATICODUODENECTOMY: DOES IT CHANGE THE FISTULA RISK PROFILE?
POSTOPERATIVE DAY 1 DRAIN AMYLASE AFTER PANCREATICODUODENECTOMY: DOES IT CHANGE THE FISTULA RISK PROFILE?
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Thumbnail for COMPARING ONCOLOGIC AND SURGICAL OUTCOMES OF ROBOTIC AND LAPAROSCOPIC PANCREATICODUODENECTOMY: A PROPENSITY-MATCHED ANALYSIS
COMPARING ONCOLOGIC AND SURGICAL OUTCOMES OF ROBOTIC AND LAPAROSCOPIC PANCREATICODUODENECTOMY: A PROPENSITY-MATCHED ANALYSIS
Minimally invasive pancreaticoduodenectomy (MIPD), or the Whipple procedure, is increasingly utilized. No study has compared laparoscopic (LPD) and robotic (RPD) approaches, and the impact of the learning curve on oncologic, technical, and post-operative outcomes remains relatively understudied…
Thumbnail for NEOADJUVANT THERAPY REDUCES NODE POSITIVITY BUT DOES NOT CONFER SURVIVAL BENEFIT VERSUS UP-FRONT RESECTION FOR RESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA: A PROPENSITY-MATCHED ANALYSIS
NEOADJUVANT THERAPY REDUCES NODE POSITIVITY BUT DOES NOT CONFER SURVIVAL BENEFIT VERSUS UP-FRONT RESECTION FOR RESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA: A PROPENSITY-MATCHED ANALYSIS
Intrahepatic Cholangiocarcinoma (iCCA) is rare but deadly. Neoadjuvant systemic therapy (NAST) is frequently employed, though its’ impact on short-term oncologic outcomes and/or survival remains relatively unknown…